Noxopharm Data Backs SOF-16’s Anti-Inflammatory Potential in Autoimmune Disease

Noxopharm Ltd. ( (AU:NOX) ) has shared an announcement.

Noxopharm has reported new data demonstrating the potential of its Sofra platform, showing that SOF-16, the active ingredient in its SOF-SKN cutaneous lupus candidate, exhibits strong anti-inflammatory effects in vitro on samples from patients with systemic lupus erythematosus and rheumatoid arthritis. The findings, generated in collaboration with Hudson Institute of Medical Research and international partners and released in a new preprint, reinforce the company’s scientific foundations and strengthen the data package it is assembling for future regulatory submissions, underscoring growing momentum behind its autoimmune pipeline.

In blood from lupus patients with a TLR7 hypersensitivity mutation, SOF-16 cut TLR7-driven inflammatory markers by more than 90 percent, while in a separate model using synovial fluid from rheumatoid arthritis patients it almost eliminated TLR7-mediated inflammatory signaling. These results suggest that Noxopharm’s approach could have broader applications across autoimmune conditions driven by TLR7 activation, potentially enhancing the company’s competitive position in immunology and offering encouraging signals for stakeholders as programs advance toward clinical development.

More about Noxopharm Ltd.

Noxopharm Limited is a clinical-stage biotechnology company based in Australia, focused on developing novel therapeutics for autoimmune and inflammatory diseases. Its Sofra technology platform underpins drug candidates such as SOF-SKN for cutaneous lupus, targeting pathways like Toll-like receptor 7 to address unmet medical needs in systemic lupus erythematosus and rheumatoid arthritis.

Average Trading Volume: 185,328

Technical Sentiment Signal: Sell

Current Market Cap: A$23.66M

Find detailed analytics on NOX stock on TipRanks’ Stock Analysis page.